Extrawell Pharmaceutical Holdings 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Yi Xie

최고 경영자

HK$1.4m

총 보상

CEO 급여 비율	94.9%
CEO 임기	10.9yrs
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	13.5yrs

최근 관리 업데이트

Recent updates

Here's Why Extrawell Pharmaceutical Holdings (HKG:858) Can Afford Some Debt

Mar 18

Extrawell Pharmaceutical Holdings (HKG:858) Is Making Moderate Use Of Debt

Dec 01

We Think That There Are Some Issues For Extrawell Pharmaceutical Holdings (HKG:858) Beyond Its Promising Earnings

Aug 04

Is Extrawell Pharmaceutical Holdings (HKG:858) Using Debt Sensibly?

Mar 15

Some Shareholders May Object To A Pay Rise For Extrawell Pharmaceutical Holdings Limited's (HKG:858) CEO This Year

Aug 20

CEO 보상 분석

Yi Xie 의 보수는 Extrawell Pharmaceutical Holdings 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	HK$1m	HK$1m	-HK$163m
Dec 31 2023	n/a	n/a	-HK$159m
Sep 30 2023	n/a	n/a	-HK$154m
Jun 30 2023	n/a	n/a	-HK$13m
Mar 31 2023	HK$1m	HK$1m	HK$129m
Dec 31 2022	n/a	n/a	HK$109m
Sep 30 2022	n/a	n/a	HK$88m
Jun 30 2022	n/a	n/a	HK$109m
Mar 31 2022	HK$1m	HK$1m	HK$131m
Dec 31 2021	n/a	n/a	HK$12m
Sep 30 2021	n/a	n/a	-HK$107m
Jun 30 2021	n/a	n/a	-HK$114m
Mar 31 2021	HK$1m	HK$1m	-HK$121m
Dec 31 2020	n/a	n/a	HK$6m
Sep 30 2020	n/a	n/a	HK$133m
Jun 30 2020	n/a	n/a	HK$108m
Mar 31 2020	HK$1m	HK$1m	HK$83m
Dec 31 2019	n/a	n/a	HK$73m
Sep 30 2019	n/a	n/a	HK$63m
Jun 30 2019	n/a	n/a	HK$63m
Mar 31 2019	HK$1m	HK$1m	HK$64m
Dec 31 2018	n/a	n/a	HK$51m
Sep 30 2018	n/a	n/a	HK$39m
Jun 30 2018	n/a	n/a	HK$34m
Mar 31 2018	HK$1m	HK$1m	HK$30m

보상 대 시장: Yi 의 총 보상 ($USD 178.05K )은 Hong Kong 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 233.11K ).

보상과 수익: Yi 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Yi Xie (61 yo)

10.9yrs

테뉴어

HK$1,386,000

보상

Dr. Yi Xie, Ph.D. serves as the Chief Executive Officer of Extrawell Pharmaceutical Holdings Ltd. Dr. Xie is one of the founders of United Gene group of companies in the PRC. Dr. Xie is responsible for res...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Yi Xie	Executive Chairman & CEO	10.9yrs	HK$1.39m	데이터 없음
Yi Lou	Executive Director	16.1yrs	HK$557.00k	데이터 없음
Yong Cheng	Deputy CEO & Executive Director	10.9yrs	HK$713.00k	6.14% HK$ 7.9m
Yi Guo	Executive Director	1.6yrs	데이터 없음	데이터 없음
Sau Kuen Wong	Company Secretary & Executive Director	16.1yrs	HK$940.00k	데이터 없음
Yumin Mao	Honorary Chairman and Chief Scientific Advisor	no data	데이터 없음	7.95% HK$ 10.3m
Lin Hu Fang	Independent Non-Executive Director	23.8yrs	HK$70.00k	데이터 없음
Song Jin	Independent Non-Executive Director	20.2yrs	HK$70.00k	데이터 없음
Li Zeng	Independent Non-Executive Director	less than a year	데이터 없음	데이터 없음

13.5yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: 858 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 13.5 년).

Extrawell Pharmaceutical Holdings 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Extrawell Pharmaceutical Holdings Limited, Annual General Meeting, Aug 23, 2024

Extrawell Pharmaceutical Holdings Limited Announces Board and Committee Changes

Extrawell Pharmaceutical Holdings Limited, Annual General Meeting, Aug 25, 2023

Extrawell Pharmaceutical Holdings Limited Announces Demise of Mr. Xue Jing Lun, Independent Non-Executive Director, and A Member of Each of the Audit Committee, Remuneration Committee and Nomination Committee

Less than half of directors are independent

Extrawell Pharmaceutical Holdings Limited Announces Management Changes

Recent updates

Extrawell Pharmaceutical Holdings Limited to Report First Half, 2025 Results on Nov 29, 2024

New major risk - Share price stability

New major risk - Market cap size

Full year 2024 earnings released: HK$0.068 loss per share (vs HK$0.054 profit in FY 2023)

Extrawell Pharmaceutical Holdings Limited, Annual General Meeting, Aug 23, 2024

Full year 2024 earnings released: HK$0.068 loss per share (vs HK$0.054 profit in FY 2023)

Extrawell Pharmaceutical Holdings Limited to Report Fiscal Year 2024 Results on Jun 28, 2024

Extrawell Pharmaceutical Holdings Limited Announces Board and Committee Changes

Here's Why Extrawell Pharmaceutical Holdings (HKG:858) Can Afford Some Debt

New major risk - Share price stability

New major risk - Market cap size

First half 2024 earnings released: HK$0.099 loss per share (vs HK$0.019 profit in 1H 2023)

Extrawell Pharmaceutical Holdings (HKG:858) Is Making Moderate Use Of Debt

New major risk - Revenue and earnings growth

Extrawell Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Nov 29, 2023

New minor risk - Share price stability

Full year 2023 earnings released: EPS: HK$0.054 (vs HK$0.055 in FY 2022)

Extrawell Pharmaceutical Holdings Limited, Annual General Meeting, Aug 25, 2023

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: HK$0.054 (vs HK$0.055 in FY 2022)

New minor risk - Financial data availability

Extrawell Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2023

Extrawell Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Jun 29, 2023

Extrawell Pharmaceutical Holdings Limited Announces Demise of Mr. Xue Jing Lun, Independent Non-Executive Director, and A Member of Each of the Audit Committee, Remuneration Committee and Nomination Committee

First half 2023 earnings released: EPS: HK$0.019 (vs HK$0.037 in 1H 2022)

Extrawell Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 September 2022

Less than half of directors are independent

Extrawell Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Nov 29, 2022

Extrawell Pharmaceutical Holdings Limited Announces Management Changes

We Think That There Are Some Issues For Extrawell Pharmaceutical Holdings (HKG:858) Beyond Its Promising Earnings

Full year 2022 earnings released: EPS: HK$0.055 (vs HK$0.051 loss in FY 2021)

Extrawell Pharmaceutical Holdings Limited, Annual General Meeting, Aug 30, 2022

Full year 2022 earnings released

Extrawell Pharmaceutical Holdings Limited Provides Earnings Guidance for the Year Ended March 31, 2022

Extrawell Pharmaceutical Holdings Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Less than half of directors are independent

Is Extrawell Pharmaceutical Holdings (HKG:858) Using Debt Sensibly?

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Some Shareholders May Object To A Pay Rise For Extrawell Pharmaceutical Holdings Limited's (HKG:858) CEO This Year

Full year 2021 earnings released: HK$0.051 loss per share (vs HK$0.035 profit in FY 2020)

Extrawell Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended March 31, 2021

First half 2021 earnings released: EPS HK$0.031

First half 2021 earnings released: EPS HK$0.031

Extrawell Pharmaceutical Holdings Limited to Report First Half, 2021 Results on Nov 27, 2020

Mao Yumin completed the acquisition of 19.14% stake in Extrawell Pharmaceutical Holdings Limited (SEHK:858) from Innovative Pharmaceutical Biotech Limited (SEHK:399).

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령